Novasenta

Drug Discovery via Single-Cell Tumor Analysis

5 add'l RD oncology

Novasenta is conducting unbiased analyses of the human tumor microenvironment to uncover new druggable targets. To develop new antibody therapeutic products, Novasenta is beginning with an in-silico discovery platform to find novel, druggable targets. This involves using their proprietary computational data mining platform to interrogate their high-dimensional single cell transcriptomics datasets gathered across multiple human cancers. From here, Novasenta is extracting relevant biological insights in the tumor microenvironment to identify novel targets across all immune cells and understand how immune networks shape the anti-tumor immune response. Novasenta is rapidly advancing a pipeline of therapeutics discovered through their approach against novel immune cell targets.